Search results for "Interleukins"

showing 10 items of 137 documents

Interleukins

1994

With interleukins (IL), a new class of potential drugs has been introduced into clinical research. These signal peptides are involved in the regulation of many physiological and pathophysiological processes. IL-1, -2, -3, -4, -6 and -11 have been tested in clinical trials. The growth promoting, growth inhibiting or immunomodulatory activities of interleukins represent the theoretical basis for large scale clinical testing, predominantly in malignant disease. Dose-dependent effects on numbers of peripheral blood cells and recovery from bone marrow failure have been demonstrated for IL-1, -3, -6 and -11. Phase III trials are in progress to determine their value for clinical practice. However,…

Clinical Trials as TopicClinical pharmacologybusiness.industryInterleukinsMelanomamedicine.medical_treatmentBone marrow failuremedicine.diseaseBioinformaticslaw.inventionClinical trialHaematopoiesisClinical researchCytokineAdjuvants ImmunologiclawRenal cell carcinomaNeoplasmsImmunologyAnimalsHumansMedicinePharmacology (medical)businessDrugs
researchProduct

Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD.

2014

Background In models of COPD, environmental stressors induce innate immune responses, inflammasome activation and inflammation. However, the interaction between these responses and their role in driving pulmonary inflammation in stable COPD is unknown. Objectives To investigate the activation of innate immunity and inflammasome pathways in the bronchial mucosa and bronchoalveolar lavage (BAL) of patients with stable COPD of different severity and control healthy smokers and non-smokers. Methods Innate immune mediators (interleukin (IL)-6, IL-7, IL-10, IL-27, IL-37, thymic stromal lymphopoietin (TSLP), interferon γ and their receptors, STAT1 and pSTAT1) and inflammasome components (NLRP3, NA…

EXPRESSIONMaleINTERLEUKIN-6InflammasomesCOPD PathologyChronic Obstructive Pulmonary DiseaseRespiratory SystemImmunity NLRP3 COPDBronchiReceptors Cell SurfaceRespiratory MucosaPULMONARYInterferon-gammaPulmonary Disease Chronic ObstructiveMARKERSThymic Stromal LymphopoietinSPUTUMNLR Family Pyrin Domain-Containing 3 ProteinCytokine Receptor gp130Humans1506HMGB1 ProteinAdaptor Proteins Signal TransducingAgedScience & TechnologyRECEPTORInterleukinsSmoking1103 Clinical SciencesMiddle AgedInterleukin-1 Receptor-Like 1 ProteinImmunity InnateInnate Immunityrespiratory tract diseasesANTIINFLAMMATORY CYTOKINESTAT1 Transcription FactorCase-Control StudiesT-CELLSASTHMACytokinesFemaleCOPD Pathology Innate ImmunityCarrier ProteinsLife Sciences & BiomedicineBronchoalveolar Lavage FluidSMOKERSThorax
researchProduct

The Mediating Effect of Different Exercise Programs on the Immune Profile of Frail Older Women with Cognitive Impairment.

2020

Background: Frail individuals experience an accelerated immunosenescence, and exercise has been identified as a therapy to promote a better inflammatory environment. Objective: To analyze the effects of 28-weeks of two different exercise protocols on the functional fitness and immune profiles of institutionalized pre-frail and frail women with mild cognitive impairment. Methods: Participants residing in care homes (n=60, 81±7.84 years old) were randomized into three groups: a chair elastic band muscle-strength exercise (CSE, n=21; 81±4.79), a chair multimodal exercise (CME, n=20; 80±8.19), and a control non-exercise (CGne, n=19; 80±10.01). Both CME and CSE groups performed progressive circ…

Functional trainingmedicine.medical_specialtyCare homesFrail ElderlyPhysical fitnessDisease03 medical and health sciences0302 clinical medicineImmune systemDrug DiscoveryMedicineHumansCognitive Dysfunction030212 general & internal medicineCognitive impairmentBalance (ability)AgedPharmacologyAged 80 and overbusiness.industryInterleukinsImmunosenescenceExercise TherapyPhysical therapyFemalebusiness030217 neurology & neurosurgeryBiomarkersCurrent pharmaceutical design
researchProduct

Optimal therapy in hepatitis C virus genotypes 2 and 3 patients.

2011

Current guidelines recommend that patients with genotype 2 (G2) and 3 (G3) chronic hepatitis C be treated with pegylated interferon (PEG-IFN) plus low doses of ribavirin (800 mg/day) for 24 weeks, resulting in a sustained virological response (SVR) rate of approximately 80%. Considering these high response rates, several recent randomized trials have assessed whether shorter treatment (12-16 weeks) could be cost-effective in these patients. The results of these studies vary but suggest better responsiveness in G2 patients, and overall, do not strongly support reducing treatment to G3, viral load < 400 000 IU, low fibrosis, no metabolic cofactors), shorter treatment is as effective as standa…

GenotypeInterleukinsInterferon-alphaStandard of CareHepacivirusInterferon alpha-2Antiviral AgentsHepatitis CPolymorphism Single NucleotideRecombinant ProteinsPolyethylene GlycolsRibavirinhcvHumansInterferonsLiver international : official journal of the International Association for the Study of the Liver
researchProduct

The many roads to inflammatory bowel diseases.

2006

Two independent studies by Rakoff-Nahoum et al. (2006) and Uhlig et al. (2006) in this issue of Immunity have illuminated a unique pathogenic role of innate immunity via Toll-like receptor and interleukin-23 signaling, respectively, in intestinal inflammation. These data define new roads to gut inflammation and future avenues for therapy.

Gut inflammationInnate immune systemInterleukinsImmunologyToll-Like ReceptorsInflammatory Bowel DiseasesBiologyInflammatory Bowel DiseasesInterleukin-12Interleukin-23Immunity InnateInfectious DiseasesImmunityIntestinal inflammationImmunologyImmunology and AllergyAnimalsSignal TransductionImmunity
researchProduct

Interferon-λ and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection.

2015

The epithelium is the main entry point for many viruses, but the processes that protect barrier surfaces against viral infections are incompletely understood. Here we identified interleukin 22 (IL-22) produced by innate lymphoid cell group 3 (ILC3) as an amplifier of signaling via interferon-λ (IFN-λ), a synergism needed to curtail the replication of rotavirus, the leading cause of childhood gastroenteritis. Cooperation between the receptor for IL-22 and the receptor for IFN-λ, both of which were 'preferentially' expressed by intestinal epithelial cells (IECs), was required for optimal activation of the transcription factor STAT1 and expression of interferon-stimulated genes (ISGs). These d…

ImmunologyImmunoblottingMolecular Sequence DataGene ExpressionMice Transgenicmedicine.disease_causeRotavirus InfectionsCell LineMadin Darby Canine Kidney CellsInterleukin 22DogsInterferonRotavirusChlorocebus aethiopsmedicineImmunology and AllergyAnimalsHumansSTAT1Intestinal MucosaReceptors CytokineVero CellsMice KnockoutbiologyReverse Transcriptase Polymerase Chain ReactionInterleukinsInnate lymphoid cellInterleukinDrug SynergismEpithelial CellsVirology3. Good healthIntestinesMice Inbred C57BLSTAT1 Transcription FactorViral replicationImmunologybiology.proteinVero cellCytokinesCaco-2 CellsHT29 Cellsmedicine.drugNature immunology
researchProduct

Editorial: CSF1R, CSF-1, and IL-34, a "menage a trois" conserved across vertebrates.

2010

Abstract Editorial discusses the perspectives opened by the recently discovered IL-34, its conservation across species in the biology of the cytokine CSF-1, and identification of a new CSF-1R ligand that could together account for the well-known heterogeneity of monocytes.

InterleukinsMacrophage Colony-Stimulating FactorMacrophagesImmunologyReceptor Macrophage Colony-Stimulating FactorCell BiologyBiologymedicine.anatomical_structureOsteoclastImmunologyVertebratesInterleukin 34medicineImmunology and AllergyMacrophageAnimalsHumansReceptorSignal TransductionJournal of leukocyte biology
researchProduct

Induction of regulatory Tr1 cells and inhibition of TH17 cells by IL-27

2011

Accumulating evidence indicates that IL-27, a member of the IL-12 family of cytokines, alleviates the severity of autoimmune diseases in both mice and men. The IL-27-induced activation of signal transducer and activator of transcription (Stat)1 and Stat3 promotes the generation of IL-10- producing type 1 regulatory T (Tr1) cells that inhibit effector T cells. In addition, IL-27 also suppresses the development of pathogenic IL-17-producing CD4(+) T cells (T(H)17) cells suggesting that pharmacological manipulations of IL-27 signaling pathway could be exploited therapeutically in regulating tissue inflammation. Here, we review how IL-27 controls inflammation through the regulation of Tr1 and T…

Interleukins/immunologyImmunologyInterleukin-10/biosynthesis/immunologyT-Lymphocytes Regulatory/immunologyddc:616.07T-Lymphocytes RegulatoryArticleAutoimmune Diseases03 medical and health sciences0302 clinical medicineImmunology and AllergyCytotoxic T cellTh17 Cells/immunologyAnimalsHumansIL-2 receptorSTAT3STAT4030304 developmental biology0303 health sciencesbiologyZAP70InterleukinsFOXP33. Good healthCell biologyddc:616.8Interleukin-10Interleukin 10Autoimmune Diseases/immunologyImmunologyInterleukin 12biology.proteinTh17 Cells030215 immunology
researchProduct

Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity

2013

Jak/Tyk proteins have recently aroused as possible therapeutic targets for the treatment of psoriasis. In psoriasis, these proteins signal through STAT molecules including STAT3, and STAT3 expression and activation has been shown augmented in psoriatic lesions. Here, we characterized the expression of Jak/Tyk proteins in lesional compared with non-lesional psoriatic skin. Jak1, Jak2 mRNA and protein and Tyk2 mRNA appeared to be downregulated, whereas Jak3 mRNA expression was increased. Moreover, STAT3 expression and activation was examined in psoriasis. STAT3 is activated at two phosphorylation sites: Tyr705 and Ser727. Both phosphorylation sites were phosphorylated in lesional psoriatic sk…

KeratinocytesSTAT3 Transcription FactorTranscription GeneticMAP Kinase Signaling SystemBiopsyp38 mitogen-activated protein kinasesPrimary Cell CultureGene ExpressionDermatologyBiochemistrystatInterleukin 20PsoriasisSerinemedicineHumansPsoriasisRNA MessengerPhosphorylationSTAT3Molecular BiologySkinTYK2 KinasebiologyInterleukin-6InterleukinsJanus Kinase 3Janus Kinase 1Janus Kinase 2medicine.diseaseTyrosine kinase 2biology.proteinCancer researchPhosphorylationTumor necrosis factor alphaSignal Transduction
researchProduct

Neuroendocrine Modulation of IL-27 in Macrophages

2017

Abstract Heterodimeric IL-27 (p28/EBV-induced gene 3) is an important member of the IL-6/IL-12 cytokine family. IL-27 is predominantly synthesized by mononuclear phagocytes and exerts immunoregulatory functional activities on lymphocytic and nonlymphocytic cells during infection, autoimmunity or neoplasms. There is a great body of evidence on the bidirectional interplay between the autonomic nervous system and immune responses during inflammatory disorders, but so far IL-27 has not been defined as a part of these multifaceted neuroendocrine networks. In this study, we describe the role of catecholamines (as mediators of the sympathetic nervous system) related to IL-27 production in primary …

Lipopolysaccharides0301 basic medicinemedicine.medical_specialtySympathetic nervous systemSympathetic Nervous SystemEpinephrinemedicine.medical_treatmentImmunologyInflammationMiceNorepinephrine03 medical and health sciences0302 clinical medicineFormoterol FumarateInternal medicineThiadiazolesmedicineAnimalsImmunology and AllergyAlbuterolCells CulturedAnthracenesInflammationSulfonamidesbiologyInterleukinsMacrophagesZymosanTLR7Macrophage ActivationShock SepticInterleukin-10Receptors AdrenergicToll-Like Receptor 3Mice Inbred C57BLTLR2Interleukin 10Poly I-C030104 developmental biologyCytokineEndocrinologymedicine.anatomical_structureIntegrin alpha Mbiology.proteinTLR4medicine.symptomSignal Transduction030215 immunologyThe Journal of Immunology
researchProduct